You are here

monoclonal antibodies

Nascent Biotech to Begin Phase II Clinical Trials for Brain Cancer

Nascent Biotech to Begin Phase II Clinical Trials for Brain Cancer

BioSpace

Nascent Biotech

clinical trials

monoclonal antibodies

Flag link:

CDC advisers endorse RSV monoclonal antibody for infants, high-risk young children

CDC advisers endorse RSV monoclonal antibody for infants, high-risk young children

Stat

monoclonal antibodies

Flag link:

Evotec's latest DOD contract provides $74M to tackle mpox

Evotec's latest DOD contract provides $74M to tackle mpox

Fierce Biotech

drug development

monoclonal antibodies

Department of Defense

Flag link:

FDA advisers recommend approval of monoclonal antibody to protect newborns and young children from RSV

FDA advisers recommend approval of monoclonal antibody to protect newborns and young children from RSV

Stat

monoclonal antibodies

Flag link:

Amgen's denosumab shows promise in small, NIH-funded rare bone disease study

Amgen's denosumab shows promise in small, NIH-funded rare bone disease study

Endpoints

clinical trials

monoclonal antibodies

Flag link:

Reeling from AstraZeneca's termination of pneumonia collab, Aridis lays off 20% of staff

Reeling from AstraZeneca's termination of pneumonia collab, Aridis lays off 20% of staff

Fierce Biotech

Aridis Pharmaceuticals

monoclonal antibodies

Flag link:

Acumen reveals late-stage clinical trial plans in early Alzheimer’s disease

Acumen reveals late-stage clinical trial plans in early Alzheimer’s disease

Clinical Trials Arena

Acumen Pharmaceuticals

clinical trials

Alzheimer's disease

monoclonal antibodies

Flag link:

Disc Medicine pays $10M upfront for monoclonal antibody for rare blood disorder, cancer

Disc Medicine pays $10M upfront for monoclonal antibody for rare blood disorder, cancer

Endpoints

Mabwell Therapeutics

monoclonal antibodies

Flag link:

Lilly's Covid-19 mAb no longer authorized due to Omicron subvariants, FDA says

Lilly's Covid-19 mAb no longer authorized due to Omicron subvariants, FDA says

Endpoints

monoclonal antibodies

Flag link:

Kineta, Merck Strike Deal to Pair Anti-VISTA Antibody with Keytruda

Kineta, Merck Strike Deal to Pair Anti-VISTA Antibody with Keytruda

BioSpace

monoclonal antibodies

Flag link:

Biogen’s Antibody Lupus Treatment Shows Mid-Stage Promise

Biogen’s Antibody Lupus Treatment Shows Mid-Stage Promise

BioSpace

systemic lupus erythematosus

monoclonal antibodies

clinical trials

Flag link:

Pursuing AbbVie and J&J, Innovent hits primary endpoint in phase 2 psoriasis trial

Pursuing AbbVie and J&J, Innovent hits primary endpoint in phase 2 psoriasis trial

Fierce Biotech

monoclonal antibodies

clinical trials

Flag link:

United BioPharma's Study Reveals New Class of Monoclonal Antibody for Effective Relief of Urticaria Symptoms

United BioPharma's Study Reveals New Class of Monoclonal Antibody for Effective Relief of Urticaria Symptoms

Drugs.com

United BioPHarma

chronic spontaneous urticaria

clinical trials

monoclonal antibodies

Flag link:

Roche, Genentech sign license deal with Kiniksa for vixarelimab

Roche, Genentech sign license deal with Kiniksa for vixarelimab

Pharmaceutical Business Review

Kiniksa Pharmaceuticals

monoclonal antibodies

Flag link:

Survey puts spotlight on US neurologists’ response to CMS Alzheimer drugs decision

Survey puts spotlight on US neurologists’ response to CMS Alzheimer drugs decision

Biopharma Reporter

monoclonal antibodies

Alzheimer's disease

Flag link:

FDA cuts off use of GSK's Covid treatment in almost half of the US as BA.2 spreads

FDA cuts off use of GSK's Covid treatment in almost half of the US as BA.2 spreads

Endpoints

Vir Biotechnology

monoclonal antibodies

Flag link:

Officials limit an antibody therapy, saying it’s ineffective against BA.2 variant of Omicron

Officials limit an antibody therapy, saying it’s ineffective against BA.2 variant of Omicron

Stat

Vir Biotechnology

monoclonal antibodies

Flag link:

In year 3 of the pandemic, a new Covid-19 biotech takes flight with an antibody combo and Takeda's ex-vaccines chief at the helm

In year 3 of the pandemic, a new Covid-19 biotech takes flight with an antibody combo and Takeda's ex-vaccines chief at the helm

Endpoints

Aerium Therapeutics

monoclonal antibodies

Flag link:

Resistance mutations found in those receiving GSK and Vir’s monoclonal for Delta, new research shows

Resistance mutations found in those receiving GSK and Vir’s monoclonal for Delta, new research shows

Endpoints

monoclonal antibodies

Flag link:

AstraZeneca and Neurimmune close agreement to develop monoclonal antibody, NI006

AstraZeneca and Neurimmune close agreement to develop monoclonal antibody, NI006

Biopharma Reporter

monoclonal antibodies

transthyretin amyloid cardiomyopathy

Flag link:

Pages